Phase 2 IND submission targeted for the second half of 2026- Demonstrating the competitiveness of GC Biopharma's mRNA platform   YONGIN, South Korea, Dec. 22, 2025 /PRNewswire/ -- GC Biopharma (006280 ...

A team led by Rensselaer Polytechnic Institute (RPI) professors Georges Belfort, Ph.D. (PI), and Pankaj Karande, Ph.D. (co-PI ...

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...

Stanford Medicine investigators have unearthed the biological process by which mRNA-based vaccines for COVID-19 can cause ...

FUJIFILM Corporation today announced the completion of one of Japan’s largest bio CDMO*1 facilities (the new plant) at the ...

A newly revealed molecular tug-of-war may have implications for better understanding how a multitude of diseases and ...

RNA vaccines, such as those used against COVID-19, are effective at generating antibody responses. These antibodies are ...

MIT and Broad Institute researchers have developed an mRNA approach that temporarily programs liver cells to produce ...

As support from the U.S. government has evaporated, Moderna is leaning on an old ally to carry plans for its prospective mRNA ...

Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...

New data highlight liver-encoded delivery of immune modulators as a strategy to mitigate age-related immune dysfunction.

As people age, their immune system function declines. T cell populations become smaller and can't react to pathogens as ...